Fei Shen, Director, Global Compound Development Team Leader (CDTL) at Johnson & Johnson, shared on LinkedIn:
“Very proud to see the first-in-human results for pasritamig + JNJ-9401 (PSMAxCD28) presented at SITC 2026, which provided important early proof of concept for this strategy in solid tumors. The combination brings together KLK2×CD3 T-cell engagement and PSMA×CD28 costimulation, a first-ever dual-antigen (KLK2+PSMA) strategy designed to provide complementary signals (CD3+CD28) to fully activate T cells against prostate cancer.
Heartfelt congratulations to the entire team for this important milestone, years of hard work and for continuing to push the boundaries of immunotherapy in solid tumors. I’m incredibly proud of what this team has accomplished and excited to see where this science can take us next.
Let’s turn the immunologically cold tumors ‘hotter’!
You can also read: CIPHER Phase 2 Trial: Carboplatin in HRR-Altered Metastatic Castration-Resistant Prostate Cancer
